



## PRESS RELEASE

### New contracts awarded for Quinvaxem<sup>®</sup> and Hepavax-Gene<sup>®</sup>

**Leiden, The Netherlands (September 23, 2008)** – Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that supranational organizations awarded Crucell new contracts of \$140 million for supplies of Quinvaxem<sup>®</sup> and Hepavax-Gene<sup>®</sup> for the period 2008 - 2009, bringing the total for the period 2007 - 2009 to \$0.5 billion.

These contracts are in addition to the December 1, 2006 announcement for the award of over \$230 million for Crucell's Quinvaxem<sup>®</sup> and Hepavax-Gene<sup>®</sup> vaccines, and the new contracts communicated on May 13, 2008 of \$130 million for supplies of Quinvaxem<sup>®</sup> in 2008 and 2009.

"We are very excited to have received additional Quinvaxem<sup>®</sup> contracts bringing the total value of the contracts awarded to date to \$0.5 billion. These awards further confirm the superior quality of our pentavalent vaccine and the continued growth we expect from Quinvaxem<sup>®</sup>" said Ronald Brus, Crucell's Chief Executive Officer.

#### Forward-looking statements

*This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on May 7, 2008, and the section entitled "Risk Factors". The Company prepares its financial statements under International Financial Reporting Standards (IFRS).*

#### About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharma company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6<sup>®</sup> production technology. The Company licenses its PER.C6<sup>®</sup> technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit [www.crucell.com](http://www.crucell.com).



**Calendar:**

1 October 2008 Phase I U.S. study presented at RITA conference Atlanta  
11 November 2008 Q3 Results 2008  
17 February 2009 Q4 Results 2008

**For further information please contact:**

Crucell N.V.  
Oya Yavuz  
Director Corporate Communications & Investor Relations  
Tel. +31-(0)71-519 7064  
[ir@crucell.com](mailto:ir@crucell.com)  
[www.crucell.com](http://www.crucell.com)